R/R SS
Showing 1 - 25 of >10,000
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Italy (R-DHAP, Pola-R-DHAP)
Not yet recruiting
- Diffuse Large B Cell Lymphoma Refractory
- Diffuse Large B-cell Lymphoma Recurrent
-
Alessandria, Italy
- +39 more
Jul 28, 2023
Lymphoma, Large B-Cell, Diffuse (DLBCL) Trial in Jerusalem, Seoul, Warszawa (Zilovertamab Vedotin, Cyclophosphamide,
Recruiting
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Zilovertamab Vedotin
- +6 more
-
Victoria, British Columbia, Canada
- +19 more
Jan 19, 2023
Multiple Organ Dysfunction With Severe Endotoxemia Trial in Moscow (hemoperfusion with polymyxin B)
Recruiting
- Multiple Organ Dysfunction With Severe Endotoxemia
- hemoperfusion with polymyxin B
-
Moscow, Russian FederationPetrovsky National Reasearch Centre of Surgery
Sep 27, 2022
Pleural Mesothelioma Trial in Italy (Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab)
Not yet recruiting
- Pleural Mesothelioma
- Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
-
Rozzano, MI, Italy
- +5 more
Nov 30, 2023
Diffuse Large B Cell Lymphoma Trial in Italy (Treatment plan)
Completed
- Diffuse Large B Cell Lymphoma
- Treatment plan
-
Milano, MI, Italy
- +18 more
Feb 15, 2022
Lung Cancer, Non Small Cell Lung Cancer, NSCLC Stage I Trial in Canada (Selective Targeted Sampling, Systematic Sampling)
Completed
- Lung Cancer
- +3 more
- Selective Targeted Sampling
- Systematic Sampling
-
Edmonton, Alberta, Canada
- +6 more
Jul 25, 2022
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and
Not yet recruiting
- HER2+ Advanced Breast Cancer
- Other Solid Tumors
- ADCC-R-Epo-R T-cells + Trastuzumab
- +2 more
- (no location specified)
Aug 31, 2023
Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
-
Shanghai, Shanhai, ChinaRuijin Hospital
Sep 29, 2023
B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- HY004
- +2 more
- (no location specified)
Aug 18, 2023
Time for R Anastomosis; Complication Related to Anastomosis Trial in Yangzhou (R anastomosis)
Completed
- Time for R Anastomosis; Complication Related to Anastomosis
- R anastomosis
-
Yangzhou, Jiangsu, ChinaNorthern Jiangsu People's Hospital
Apr 11, 2023
Arthritis, Rheumatoid Trial in Lebanon (R-2487)
Not yet recruiting
- Arthritis, Rheumatoid
-
Lebanon, New HampshireDartmouth Hitchcock Medical Center (DHMC)
Jul 18, 2023
Non-invasive Continuous Hemodynamic Measurement From Task Force
Not yet recruiting
- Hemodynamic Measurement
- +2 more
- non-invasive device (Task Force CORE(R) and Task Force CARDIO(R)
-
Graz, Styria, AustriaMedical University of Graz
Aug 23, 2023
Follicular Lymphoma Trial in Italy (Immunochemo regimen: Rituximab-bendamustine (Arm A), Immunochemo regimen:
Recruiting
- Follicular Lymphoma
- Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
- +9 more
-
Barletta, Barletta Andria Trani, Italy
- +68 more
Oct 13, 2022
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States
Completed
- Non-Hodgkin's Lymphoma, Relapsed
- +8 more
- PBCAR20A
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)
Recruiting
- B-cell Non Hodgkin Lymphoma
- regimen with BTK inhibitor +Anti-CD19 CAR T cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Kunming (Anti-GPRC5D CAR-T cells infusion)
Recruiting
- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory
- Anti-GPRC5D CAR-T cells infusion
-
Kunming, Yunnan, China
- +1 more
Feb 21, 2023